{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:58:29Z","timestamp":1791140309385,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002738","name":"Assistance Publique - H\u00f4pitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["754740"],"award-info":[{"award-number":["754740"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-16-RHUS-0001"],"award-info":[{"award-number":["ANR-16-RHUS-0001"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bbi.2024.09.005","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T13:09:28Z","timestamp":1725455368000},"page":"177-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial"],"prefix":"10.1016","volume":"123","author":[{"given":"Marion","family":"Leboyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Foiselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Tchitchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryad","family":"Tamouza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lorenzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Romain","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaele","family":"Arrouasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Le Corvoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Le Dudal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Ellul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rosenzwajg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Klatzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbi.2024.09.005_b0005","first-page":"826","article-title":"Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer\u2019s disease mice","volume":"140","author":"Alves","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.bbi.2024.09.005_b0010","first-page":"3","article-title":"Discovery of potent and highly selective inhibitors of GSK3b","volume":"1","author":"An","year":"2012","journal-title":"Probe Reports from the NIH Molecular Libraries Program"},{"key":"10.1016\/j.bbi.2024.09.005_b0015","doi-asserted-by":"crossref","unstructured":"Baer, L., Blais, M.A. (Eds.), 2010. Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health. Humana Press, Totowa, NJ. doi: 10.1007\/978-1-59745-387-5.","DOI":"10.1007\/978-1-59745-387-5"},{"key":"10.1016\/j.bbi.2024.09.005_b0020","doi-asserted-by":"crossref","first-page":"e003500","DOI":"10.1136\/rmdopen-2023-003500","article-title":"Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study","volume":"10","author":"Barde","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.bbi.2024.09.005_b0025","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.cmet.2023.08.010","article-title":"Regulatory T cells require IL6 receptor alpha signaling to control skeletal muscle function and regeneration","volume":"35","author":"Becker","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbi.2024.09.005_b0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13229-019-0269-1","article-title":"Persistence of dysfunctional natural killer cells in adults with high-functioning autism spectrum disorders: stigma\/consequence of unresolved early infectious events?","volume":"10","author":"Bennabi","year":"2019","journal-title":"Mol. Autism."},{"key":"10.1016\/j.bbi.2024.09.005_b0035","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1001\/jamapsychiatry.2013.1111","article-title":"Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study","volume":"70","author":"Benros","year":"2013","journal-title":"JAMA Psychiat."},{"key":"10.1016\/j.bbi.2024.09.005_b0040","unstructured":"Bensimon, G., Leigh, P.N., Group, M.S., 2022. Modifying immune response and outcomes in ALS (MIROCALS): design and results of a phase 2b, double-blind randomized placebocontrolled trial of low dose interleukin-2 (ld IL2) in ALS., in: Platform Communications: Abstract Book. Presented at the 33rd International Symposium on ALS\/MND, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2022)."},{"key":"10.1016\/j.bbi.2024.09.005_b0045","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2249.2007.03562.x","article-title":"Up-regulation of the phosphoinositide 3-kinase pathway in human lamina propria T lymphocytes","volume":"151","author":"Braunstein","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbi.2024.09.005_b0050","first-page":"28","article-title":"The clinical global impressions scale","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.bbi.2024.09.005_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102844","article-title":"Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): a phase 2a randomised, double-blind, placebo-controlled trial","volume":"59","author":"Camu","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbi.2024.09.005_b0060","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.4049\/jimmunol.2000136","article-title":"Cutting edge: inhibition of glycogen synthase kinase 3 activity induces the generation and enhanced suppressive function of human IL-10+ FOXP3+-induced regulatory T cells","volume":"205","author":"Cheng","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbi.2024.09.005_b0065","doi-asserted-by":"crossref","unstructured":"do Prado, C.H., Rizzo, L.B., Wieck, A., Lopes, R.P., Teixeira, A.L., Grassi-Oliveira, R., Bauer, M.E., 2013. Reduced regulatory T cells are associated with higher levels of Th1\/TH17 cytokines and activated MAPK in type 1 bipolar disorder. Psychoneuroendocrinology 38, 667\u2013676. doi: 10.1016\/j.psyneuen.2012.08.005.","DOI":"10.1016\/j.psyneuen.2012.08.005"},{"key":"10.1016\/j.bbi.2024.09.005_b0070","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A meta-analysis of cytokines in major depression","volume":"67","author":"Dowlati","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2024.09.005_b0075","unstructured":"Drexhage, H.A., 2018. Moodstratification."},{"key":"10.1016\/j.bbi.2024.09.005_b0080","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fneur.2018.00167","article-title":"Regulatory T cells as supporters of psychoimmune resilience: toward immunotherapy of major depressive disorder","volume":"9","author":"Ellul","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.bbi.2024.09.005_b0085","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bbi.2023.05.015","article-title":"Immune cell subsets in patients with bipolar disorder or schizophrenia with history of childhood maltreatment","volume":"112","author":"Foiselle","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2024.09.005_b0090","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s11481-013-9462-8","article-title":"Evidence for a dysregulated immune system in the etiology of psychiatric disorders","volume":"8","author":"Gibney","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.bbi.2024.09.005_b0095","doi-asserted-by":"crossref","unstructured":"Godin, O., Etain, B., Henry, C., Bougerol, T., Courtet, P., Mayliss, L., Passerieux, C., Azorin, J.-M., Kahn, J.-P., Gard, S., Costagliola, D., Leboyer, M., FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators, 2014. Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. J Clin Psychiatry 75, 1078\u20131085; quiz 1085. doi: 10.4088\/JCP.14m09038.","DOI":"10.4088\/JCP.14m09038"},{"issue":"Suppl 5","key":"10.1016\/j.bbi.2024.09.005_b0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1399-5618.2005.00251.x","article-title":"Benefits and limitations of antidepressants and traditional mood stabilizers for treatment of bipolar depression","volume":"7","author":"Goldberg","year":"2005","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.bbi.2024.09.005_b0105","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","article-title":"Bipolar disorder","volume":"387","author":"Grande","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bbi.2024.09.005_b0110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bbi.2015.12.003","article-title":"Deficiencies of the T and natural killer cell system in major depressive disorder: T regulatory cell defects are associated with inflammatory monocyte activation","volume":"54","author":"Grosse","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2024.09.005_b0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0165-0173(95)00015-1","article-title":"Interleukin-2 as a neuroregulatory cytokine","volume":"23","author":"Hanisch","year":"1995","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.bbi.2024.09.005_b0120","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose Interleukin-2 induces regulatory T cells and is well tolerated in patients with type-1 diabetes: results of a phase I\/II randomized, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bbi.2024.09.005_b0125","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbi.2024.09.005_b0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000343100","article-title":"Imbalance between Th17 and Treg cells may play an important role in the development of chronic unpredictable mild stress-induced depression in mice","volume":"20","author":"Hong","year":"2013","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.bbi.2024.09.005_b0135","doi-asserted-by":"crossref","unstructured":"Humrich, J.Y., Cacoub, P., Rosenzwajg, M., Pitoiset, F., Pham, H.P., Guidoux, J., Leroux, D., Vazquez, T., Riemekasten, G., Smolen, J.S., Tsokos, G., Klatzmann, D., 2022. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis annrheumdis-2022-222501. doi: 10.1136\/ard-2022-222501.","DOI":"10.1136\/ard-2022-222501"},{"key":"10.1016\/j.bbi.2024.09.005_b0140","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbi.2024.09.005_b0145","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbi.2024.09.005_b0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41590-022-01390-0","article-title":"Brain regulatory T cells","author":"Liston","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbi.2024.09.005_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103172","article-title":"The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial","volume":"144","author":"Lorenzon","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bbi.2024.09.005_b0160","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1007\/s00415-023-11690-6","article-title":"A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis","volume":"270","author":"Louapre","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.bbi.2024.09.005_b0165","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/15622975.2013.830775","article-title":"Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: Developing treatments using an integrated translational approach","volume":"15","author":"Machado-Vieira","year":"2014","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2024.09.005_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104868","article-title":"Regulatory T cells promote remyelination in the murine experimental autoimmune encephalomyelitis model of multiple sclerosis following human neural stem cell transplant","volume":"140","author":"McIntyre","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbi.2024.09.005_b0175","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mi.2014.33","article-title":"Foxp3+ regulatory T cells promote lung epithelial proliferation","volume":"7","author":"Mock","year":"2014","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.bbi.2024.09.005_b0180","doi-asserted-by":"crossref","unstructured":"Nigel Leigh, P., Bensimon, G., Payan, C., Al-Chalab, A., Andreasson, U., Dickie, B., Garlanda, C., Kirbie, J., Klassens, P., Locati, M., Malaspina, A., Masseguin, C., Muller, C., Huang Pham, H., Saker-Delye, S., Shaw, P.J., Tree, T., Zetterberg, H., the Mirocals trial Consortium, 2023. The MIROCALS Study: Efficacy of low dose IL2 in ALS and implications for ALS trial design. Presented at the Encals meeting 2023, Encals meeting 2023, Barcelona, Spain.","DOI":"10.1136\/JNNP-2023-ABN.5"},{"key":"10.1016\/j.bbi.2024.09.005_b0185","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.192.1.99","article-title":"Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase Gsk-3","volume":"192","author":"Ohteki","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbi.2024.09.005_b0190","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41582-019-0174-4","article-title":"Immunoneuropsychiatry - novel perspectives on brain disorders","volume":"15","author":"Pape","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbi.2024.09.005_b0195","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.euroneuro.2017.04.001","article-title":"Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation","volume":"27","author":"Pariante","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbi.2024.09.005_b0200","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbi.2024.02.019","article-title":"Low-dose interleukin 2 antidepressant potentiation in unipolar and bipolar depression: Safety, efficacy, and immunological biomarkers","volume":"118","author":"Poletti","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2024.09.005_b0205","doi-asserted-by":"crossref","first-page":"11177","DOI":"10.1038\/s41598-024-61865-y","article-title":"T cell activation and deficits in T regulatory cells are associated with major depressive disorder and severity of depression","volume":"14","author":"Rachayon","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbi.2024.09.005_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbi.2024.09.005_b0215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients","volume":"58","author":"Rosenzwajg","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bbi.2024.09.005_b0220","doi-asserted-by":"crossref","unstructured":"Rosenzwajg, M., Lorenzon, R., Cacoub, P., Pham, H.P., Pitoiset, F., El Soufi, K., RIbet, C., Bernard, C., Aractingi, S., Banneville, B., Beaugerie, L., Berenbaum, F., Champey, J., Chazouilleres, O., Corpechot, C., Fautrel, B., Mekinian, A., Regnier, E., Saadoun, D., Salem, J.-E., Sellam, J., Seksik, P., Daguenel-Nguyen, A., Doppler, V., Mariau, J., Vicaut, E., Klatzmann, D., 2019. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. 78, 209\u2013217. doi: 10.1136\/annrheumdis-2018-214229.","DOI":"10.1136\/annrheumdis-2018-214229"},{"key":"10.1016\/j.bbi.2024.09.005_b0225","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s00125-020-05200-w","article-title":"Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a phase I\/II randomised, double-blind, placebo-controlled, dose-finding study","volume":"63","author":"Rosenzwajg","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.bbi.2024.09.005_b0230","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbi.2024.09.005_b0235","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbi.2016.05.007","article-title":"A dynamic course of T cell defects in individuals at risk for mood disorders","volume":"58","author":"Snijders","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2024.09.005_b0240","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1038\/s41380-020-01008-7","article-title":"Natural killer cells in first-episode psychosis: an innate immune signature?","volume":"26","author":"Tarantino","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbi.2024.09.005_b0245","doi-asserted-by":"crossref","unstructured":"Villalta, S.A., Rosenthal, W., Martinez, L., Kaur, A., Sparwasser, T., Tidball, J.G., Margeta, M., Spencer, M.J., Bluestone, J.A., 2014. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci. Transl. Med. 6, 258ra142. doi: 10.1126\/scitranslmed.3009925.","DOI":"10.1126\/scitranslmed.3009925"},{"key":"10.1016\/j.bbi.2024.09.005_b0250","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.biopsych.2006.08.041","article-title":"Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder?","volume":"62","author":"Vonk","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2024.09.005_b0255","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.bbi.2024.09.005_b0260","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.2337\/db14-1322","article-title":"Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes","volume":"64","author":"Yu","year":"2015","journal-title":"Diabetes"}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159124005993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159124005993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:46:46Z","timestamp":1762314406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159124005993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":52,"alternative-id":["S0889159124005993"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2024.09.005","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.19.24310686","asserted-by":"object"}]},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2024.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}